danaher investor presentation 2022

• Danaher-stock
• News for Danaher Danaher

Danaher Reports First Quarter 2022 Results

WASHINGTON , April 21, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the first quarter 2022.

For the quarter ended April 1, 2022 , net earnings were $1.7 billion , or $2.31 per diluted common share which represents a 1.0% increase over the comparable 2021 period.  Non-GAAP adjusted diluted net earnings per common share were $2.76 which represents a 9.5% increase over the comparable 2021 period.

Revenues increased 12.0% year-over-year to $7.7 billion , with 12.0% non-GAAP core revenue growth and 8.0% non-GAAP base business core revenue growth.

Operating cash flow was $2.0 billion and non-GAAP free cash flow was $1.7 billion .

For the second quarter 2022, the Company anticipates that non-GAAP base business core revenue growth will be in the mid-single digit percent range, which includes an approximately 200 to 300 basis point headwind from the COVID-19 related shutdowns in China .

For the full year 2022, the Company continues to expect non-GAAP base business core revenue growth will be in the high-single digit percent range.

Rainer M. Blair , President and Chief Executive Officer, stated, "We had a good start to the year with results exceeding our initial expectations.  Our team successfully navigated a dynamic environment to deliver double digit core revenue growth, approximately 10% adjusted earnings per share growth and $2.0 billion of operating cash flow, despite difficult prior year comparisons.  This performance was broad based with all three of our segments delivering high-single digit or better core revenue growth.  We believe our strong execution combined with investments in innovation have driven market share gains in many of our businesses."

Danaher will discuss its results during its quarterly investor conference call today starting at 8:00 a.m. ET .  The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com , under the subheading "Events & Presentations."  A replay of the webcast will be available in the same section of Danaher's website shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.

The conference call can be accessed by dialing 866-952-8559 within the U.S. or by dialing +1 785-424-1881 outside the U.S. a few minutes before the 8:00 a.m. ET start and telling the operator that you are dialing in for Danaher's earnings conference call (Conference ID: DHRQ122).  A replay of the conference call will be available shortly after the conclusion of the call and until May 5 , 2022.  You can access the replay dial-in information on the "Investors" section of Danaher's website under the subheading "Events & Presentations."  In addition, presentation materials relating to Danaher's results have been posted to the "Investors" section of Danaher's website under the subheading "Quarterly Earnings."

ABOUT DANAHER

Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world.  Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets.  With more than 20 operating companies, Danaher's globally diverse team of approximately 80,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential .  For more information, please visit www.danaher.com .

NON-GAAP MEASURES

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings release also contains non-GAAP financial measures.  Calculations of these measures, the reasons why we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures, as applicable, and other information relating to these non-GAAP measures are included in the supplemental reconciliation schedule attached.

FORWARD-LOOKING STATEMENTS

Statements in this release that are not strictly historical, including the statements regarding the Company's expected financial performance for the second quarter and full year 2022 and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws.  There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements.  These factors include, among other things, the highly uncertain and unpredictable severity, magnitude and duration of the COVID-19 pandemic (and the related governmental, business and community responses thereto) on our business, results of operations and financial condition, the impact of our debt obligations on our operations and liquidity, deterioration of or instability in the economy, the markets we serve and the financial markets (including as a result of the COVID-19 pandemic), uncertainties relating to U.S. laws or policies, including potential changes in U.S. trade policies and tariffs and the reaction of other countries thereto, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments and successfully complete divestitures and other dispositions, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government to use, disclose and license certain intellectual property we license if we fail to commercialize it, risks relating to product, service or software defects, product liability and recalls, risks relating to product manufacturing, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole sources of supply, the impact of deregulation on demand for our products and services, the impact of climate change, or legal or regulatory measures to address climate change, labor matters and our ability to recruit, retain and motivate talented employees, international economic, political, legal, compliance, social and business factors (including the impact of the United Kingdom's separation from the European Union and the impact of the military conflict between Russia and Ukraine ), disruptions relating to man-made and natural disasters (including pandemics such as COVID-19) and pension plan costs. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2021 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the first quarter of 2022.  These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

DANAHER CORPORATION RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures.

Statement Regarding Non-GAAP Measures

Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies.  Management believes that these measures provide useful information to investors by offering additional ways of viewing Danaher Corporation's ("Danaher" or the "Company") results that, when reconciled to the corresponding GAAP measure, help our investors to:

• with respect to Adjusted Diluted Net Earnings Per Common Share, understand the long-term profitability trends of our business and compare our profitability to prior and future periods and to our peers;
• with respect to core sales and related sales measures, identify underlying growth trends in our business and compare our sales performance with prior and future periods and to our peers; and
• with respect to free cash flow and related cash flow measures (the "FCF Measure"), understand Danaher's ability to generate cash without external financings, strengthen its balance sheet, invest in its business and grow its business through acquisitions and other strategic opportunities (although a limitation of free cash flow is that it does not take into account the Company's debt service requirements and other non-discretionary expenditures, and as a result the entire free cash flow amount is not necessarily available for discretionary expenditures).

While we expect overall demand for the Company's COVID-19 related products to moderate as and to the extent the pandemic subsides, as the pandemic evolves toward endemic status we believe a level of demand for the Company's products that support COVID-19 related vaccines and therapeutics (including initiatives that seek to prevent or mitigate similar, future pandemics) and COVID-19 testing will continue.  However, on a relative basis, we expect the level of ongoing demand for products supporting COVID-19 testing will be subject to more fluctuations in demand than the level of demand for products supporting COVID-19 related vaccines and therapeutics.  Therefore, beginning with the first quarter of 2022, in addition to disclosing core revenue growth, we disclose "base business core sales growth" on a basis that excludes revenues related to COVID-19 testing and includes revenues from products that support COVID-19 related vaccines and therapeutics.  We believe this additional measure provides useful information to investors by facilitating period-to-period comparisons of our financial performance and identifying underlying growth trends in the Company's business that otherwise may be obscured by fluctuations in demand for COVID-19 testing as a result of the pandemic. 

Management uses these non-GAAP measures to measure the Company's operating and financial performance, and uses core sales and non-GAAP measures similar to Adjusted Diluted Net Earnings Per Common Share and the FCF Measure in the Company's executive compensation program.

The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons:

• With respect to Adjusted Diluted Net Earnings Per Common Share:
• Amortization of Intangible Assets.  We exclude the amortization of acquisition-related intangible assets because the amount and timing of such charges are significantly impacted by the timing, size, number and nature of the acquisitions we consummate.  While we have a history of significant acquisition activity we do not acquire businesses on a predictable cycle, and the amount of an acquisition's purchase price allocated to intangible assets and related amortization term are unique to each acquisition and can vary significantly from acquisition to acquisition.  Exclusion of this amortization expense facilitates more consistent comparisons of operating results over time between our newly acquired and long-held businesses, and with both acquisitive and non-acquisitive peer companies.  We believe however that it is important for investors to understand that such intangible assets contribute to sales generation and that intangible asset amortization related to past acquisitions will recur in future periods until such intangible assets have been fully amortized.
• Restructuring Charges.  We exclude costs incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of the size, strategic nature and planning requirements, as well as the inconsistent frequency, of such plans) from the ongoing productivity improvements that result from application of the Danaher Business System.  Because these restructuring plans are incremental to the core activities that arise in the ordinary course of our business and we believe are not indicative of Danaher's ongoing operating costs in a given period, we exclude these costs to facilitate a more consistent comparison of operating results over time.
• Other Adjustments.  With respect to the other items excluded from Adjusted Diluted Net Earnings Per Common Share, we exclude these items because they are of a nature and/or size that occur with inconsistent frequency, occur for reasons that may be unrelated to Danaher's commercial performance during the period and/or we believe that such items may obscure underlying business trends and make comparisons of long-term performance difficult.  For example, we excluded the first quarter 2022 charge for asset impairments, accruals for contractual obligations and similar items related to our Russia operations because, even though it is possible we could incur additional charges in the future, we do not believe these charges are indicative of Danaher's ongoing operating costs. 
• With respect to adjusted average common stock and common equivalent shares outstanding, Danaher's Mandatory Convertible Preferred Stock ("MCPS") Series A converted into Danaher common stock on April 15, 2022 and MCPS Series B will mandatorily convert into Danaher common stock on the mandatory conversion date, which is expected to be April 15, 2023 (unless converted or redeemed earlier in accordance with the terms of the applicable certificate of designations).  With respect to the calculation of Adjusted Diluted Net Earnings Per Common Share, we apply the "if converted" method of share dilution to the MCPS Series A and B in all applicable periods irrespective of whether such preferred shares would be dilutive or anti-dilutive in the period.  We believe this presentation provides useful information to investors by helping them understand what the net impact will be on Danaher's earnings per share-related measures once the MCPS convert into Danaher common stock.
• With respect to core sales related measures, (1) we exclude the impact of currency translation because it is not under management's control, is subject to volatility and can obscure underlying business trends, and (2) we exclude the effect of acquisitions and divested product lines because the timing, size, number and nature of such transactions can vary significantly from period-to-period and between us and our peers, which we believe may obscure underlying business trends and make comparisons of long-term performance difficult.
• With respect to the FCF Measure, we exclude payments for additions to property, plant and equipment (net of the proceeds from capital disposals) to demonstrate the amount of operating cash flow for the period that remains after accounting for the Company's capital expenditure requirements.

With respect to forecasted core sales related measures, we do not reconcile these measures to the comparable GAAP measure because of the inherent difficulty in predicting and estimating the future impact and timing of currency translation, acquisitions and divested product lines, which would be reflected in any forecasted GAAP revenue.

SOURCE Danaher Corporation

Danaher News MORE

Related stocks.

Press Releases

Danaher to present at td cowen health care conference.

Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the TD Cowen Healthcare Conference in Boston, Massachusetts on Tuesday,...

Danaher Commits to Set Science-Based, Net-Zero Greenhouse Gas Emission Reduction Targets

Danaher Corporation (NYSE: DHR) (Danaher) announced today it has committed to set science-based greenhouse gas (GHG) emission reduction targets in line with the Science Based Targets initiative...

Danaher Announces Quarterly Dividend

Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on April 26, 2024 to...

Danaher Launches Collaboration with Cincinnati Children's Hospital Medical Center Aiming to Improve Patient Safety in Early Drug Development

Danaher Beacon for Preclinical Drug Safety seeks to address major cause of failure in clinical trials Program will leverage automated liver organoid technology for drug toxicity screening Aims to...

Danaher Reports Fourth Quarter and Full Year 2023 Results

Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2023. All results in this release reflect only continuing operations unless otherwise...

Danaher, Jennifer Doudna, and Innovative Genomics Institute Launch Danaher-IGI Beacon for CRISPR Cures with Aim to Address Hundreds of Diseases Using Gene-editing Platform Solution

New collaborative research center based at University of California, Berkeley, plans to develop platform approaches that can be easily modified to develop gene-editing medicines for hundreds of...

Danaher CEO to Comment on Financial Performance

Danaher Corporation (NYSE: DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Company's fourth quarter 2023 performance in...

Danaher to Present at J.P. Morgan Healthcare Conference

Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P. Morgan Healthcare Conference in San Francisco, California on...

Danaher Schedules Fourth Quarter 2023 Earnings Conference Call

Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2023 on Tuesday, January 30, 2024 beginning at 8:00 a.m. ET and lasting...

Danaher Completes Acquisition of Abcam

Danaher Corporation (NYSE:DHR) ("Danaher") announced today it has completed its acquisition of Abcam plc (NASDAQ:ABCM) ("Abcam"). The acquisition of Abcam for $24.00 per share in cash was...

Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.24 per share of its common stock, payable on January 26, 2024 to...

Danaher to Present at Evercore ISI HealthCONx Conference

Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Evercore ISI HealthCONx Conference in Miami, Florida on Wednesday,...

Danaher appoints Christopher Riley to Executive Vice President for Biotechnology

Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), a leading global life sciences and diagnostics innovator, today announced that Christopher Riley has been appointed by its Board of...

Danaher Reports Third Quarter 2023 Results

Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the third quarter ended September 29, 2023. Net earnings refer to net earnings attributable to common shareholders....

Danaher Corporation Completes Separation of Veralto Corporation

Danaher Corporation (NYSE: DHR) announced today that it has completed the separation of its Environmental & Applied Solutions segment, through the spin-off of Veralto Corporation. Veralto will...

Danaher Schedules Third Quarter 2023 Earnings Conference Call

Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2023 on Tuesday, October 24, 2023 beginning at 8:00 a.m. ET and lasting...

Danaher to Provide Cepheid's Tuberculosis Test to the Global Fund at Cost

New agreement aims to provide greater access to millions more high-quality tuberculosis (TB) tests for people living in the least developed countries where the need is most urgent. Enables the...

Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on October 27, 2023 to...

Danaher and Veralto to Webcast Investor and Analyst Meeting

Danaher Corporation (NYSE: DHR) will host a live video webcast of Veralto's Investor and Analyst Meeting on September 6, 2023 beginning at approximately 12:00 p.m. CT. The event, which will...

Danaher to Acquire Abcam

Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Abcam plc...

Danaher Declares pro Rata Dividend of Veralto Common Stock and Announces Expected "When-issued" Trading of Veralto Common Stock

Danaher Corporation (NYSE: DHR) today announced that it expects to complete the previously announced separation of Veralto Corporation on September 30, 2023, the first day of Danaher's fiscal...

Danaher Releases 2023 Sustainability Report

Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), the global science and technology innovator, today published its 2023 Sustainability Report which conveys the depth and scope of...

Danaher Reports Second Quarter 2023 Results

Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the second quarter 2023. Net earnings refer to net earnings attributable to common shareholders. For the quarter ended...

Danaher Schedules Second Quarter 2023 Earnings Conference Call

Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2023 on Tuesday, July 25, 2023 beginning at 8:00 a.m. ET and lasting...

Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on July 28, 2023 to...

Danaher to Present at Bank of America Securities Health Care Conference

Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Bank of America Securities Health Care Conference in Las Vegas,...

Danaher Reports First Quarter 2023 Results

Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the first quarter 2023. Net earnings refer to net earnings attributable to common shareholders. For the quarter ended...

Danaher Announces Conversion Date for Series B Mandatory Convertible Preferred Stock

Danaher Corporation (NYSE: DHR) announced today that its 5.00% Series B Mandatory Convertible Preferred Stock (the "Preferred Stock"), will automatically convert into shares of the Company's...

Danaher Schedules First Quarter 2023 Earnings Conference Call

Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2023 on Tuesday, April 25, 2023 beginning at 8:00 a.m. ET and lasting...

Danaher Partners with the University of Pennsylvania's Center for Cellular Immunotherapies to Address Manufacturing Challenges Impacting the Uptake of Cell Therapies

Danaher Corporation (NYSE: DHR), a global science and technology innovator, today announced a strategic partnership with the University of Pennsylvania (Penn) focusing on cell therapy innovation....

Danaher Announces Quarterly Dividends

Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on April 28, 2023 to...

Danaher Announces New Environmental and Applied Solutions Company to Be Named Veralto

Danaher Corporation (NYSE: DHR) ("Danaher") today announced that Veralto Corporation ("Veralto" or the "Company") will be the name of the separate public company Danaher intends to create in the...

Danaher Reports Fourth Quarter and Full Year 2022 Results

Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2022. All results in this release reflect only continuing operations unless otherwise...

Danaher Corporation (NYSE: DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Company's fourth quarter 2022 performance in...

Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at...

Danaher Schedules Fourth Quarter 2022 Earnings Conference Call

Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2022 on Tuesday, January 24, 2023 beginning at 8:00 a.m. ET and lasting...

Danaher Schedules Third Quarter 2022 Earnings Conference Call

Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2022 on Thursday, October 20, 2022 beginning at 8:00 a.m. ET and lasting...

First refuelling for Russia’s Akademik Lomonosov floating NPP

!{Model.Description}

The FNPP includes two KLT-40S reactor units. In such reactors, nuclear fuel is not replaced in the same way as in standard NPPs – partial replacement of fuel once every 12-18 months. Instead, once every few years the entire reactor core is replaced with and a full load of fresh fuel.

The KLT-40S reactor cores have a number of advantages compared with standard NPPs. For the first time, a cassette core was used, which made it possible to increase the fuel cycle to 3-3.5 years before refuelling, and also reduce by one and a half times the fuel component in the cost of the electricity produced. The operating experience of the FNPP provided the basis for the design of the new series of nuclear icebreaker reactors (series 22220). Currently, three such icebreakers have been launched.

The Akademik Lomonosov was connected to the power grid in December 2019, and put into commercial operation in May 2020.

Electricity generation from the FNPP at the end of 2023 amounted to 194 GWh. The population of Pevek is just over 4,000 people. However, the plant can potentially provide electricity to a city with a population of up to 100,000. The FNPP solved two problems. Firstly, it replaced the retiring capacities of the Bilibino Nuclear Power Plant, which has been operating since 1974, as well as the Chaunskaya Thermal Power Plant, which is more than 70 years old. It also supplies power to the main mining enterprises located in western Chukotka. In September, a 490 km 110 kilovolt power transmission line was put into operation connecting Pevek and Bilibino.

Image courtesy of TVEL

• Terms and conditions
• Privacy Policy
• Newsletter sign up
• Digital Edition
• Editorial Standards

Victor Mukhin

• Scientific Program

Title : Active carbons as nanoporous materials for solving of environmental problems

However, up to now, the main carriers of catalytic additives have been mineral sorbents: silica gels, alumogels. This is obviously due to the fact that they consist of pure homogeneous components SiO2 and Al2O3, respectively. It is generally known that impurities, especially the ash elements, are catalytic poisons that reduce the effectiveness of the catalyst. Therefore, carbon sorbents with 5-15% by weight of ash elements in their composition are not used in the above mentioned technologies. However, in such an important field as a gas-mask technique, carbon sorbents (active carbons) are carriers of catalytic additives, providing effective protection of a person against any types of potent poisonous substances (PPS). In ESPE “JSC "Neorganika" there has been developed the technology of unique ashless spherical carbon carrier-catalysts by the method of liquid forming of furfural copolymers with subsequent gas-vapor activation, brand PAC. Active carbons PAC have 100% qualitative characteristics of the three main properties of carbon sorbents: strength - 100%, the proportion of sorbing pores in the pore space – 100%, purity - 100% (ash content is close to zero). A particularly outstanding feature of active PAC carbons is their uniquely high mechanical compressive strength of 740 ± 40 MPa, which is 3-7 times larger than that of  such materials as granite, quartzite, electric coal, and is comparable to the value for cast iron - 400-1000 MPa. This allows the PAC to operate under severe conditions in moving and fluidized beds.  Obviously, it is time to actively develop catalysts based on PAC sorbents for oil refining, petrochemicals, gas processing and various technologies of organic synthesis.

Victor M. Mukhin was born in 1946 in the town of Orsk, Russia. In 1970 he graduated the Technological Institute in Leningrad. Victor M. Mukhin was directed to work to the scientific-industrial organization "Neorganika" (Elektrostal, Moscow region) where he is working during 47 years, at present as the head of the laboratory of carbon sorbents.     Victor M. Mukhin defended a Ph. D. thesis and a doctoral thesis at the Mendeleev University of Chemical Technology of Russia (in 1979 and 1997 accordingly). Professor of Mendeleev University of Chemical Technology of Russia. Scientific interests: production, investigation and application of active carbons, technological and ecological carbon-adsorptive processes, environmental protection, production of ecologically clean food.   

Quick Links

• Conference Brochure
• Tentative Program